History
Company History
Onselex
2022
- Oct. 12,2022 Professor Si-young Song, Distinguished Professor and Clinician at Yonsei University College of Medicine joined as a member of Onselex CAB
- Oct. 06,2022 Professor Hosoon Choi, Chief at Hanyang University Medical Center joined as a member of Onselex CAB
- July. 04,2022 In the PK test of the ONX-1006 PANC-1 Xenograft mouse model, higher PTX was detected in the tumor tissue compared to the plasma.
- Mar. 30,2022 ONX-1006 anticancer drug, Beagle single IV administration toxicity GLP test: Confirmation of Beagle in the normal and safe state even after administration of 3 times the lethal dose of ONX-1006 (PTX 25mg/kg).
- Mar. 3,2022 Study for Anti-Tumor Effect of ONX-1006 on Tumor Growth Formed by AsPC-1 Carcinoma Cells, 5th successful statically significant Efficacy results achieved
2021
- Dec. 14, 2021 ONX-1006 GLP anticancer test (intravenous administration of rats) : Confirmation of rats in a normal and safe state after administration of 20 times the lethal dose of the paclitaxel
- Oct. 06, 2021 Completed development of ONX-2006 anticancer drug (Pills) : stomach cancer, colon cancer
- Sept. 27, 2021 ONX-1006 AsPC-1 Pancreatic Cancer Cell Xenograft Model 3rd successful Efficacy results achieved
- Aug. 10, 2021 Initiated 3rd ONX-1006 Xenograft efficacy test (with Dt&C)
- Mar. 30, 2021 Completed for entry into the national phase of the PCT international patent application
2020
- Dec. 16, 2020 Signed MDA-MB-231 xenograft ONX-1006 Breast cancer efficacy test with ChemOn
- Aug. 31, 2020 Signed a Pre-clinical trial agreement of ONX-1006
- Aug. 27, 2020 Signed an agreement for non-clinical trials of ONX-1006 oncologic efficacy
- Aug. 25, 2020 Paid-in capital increase by allocation to third parties (Founding capital : KRW 1,628,656,000, Total amount of investment on 28,656 , new shares: KRW 2,579,040,000)
- Jul. 13, 2020 Signed an exclusive Global Nano Cancer Licensing Agreement
- Jul. 10, 2020 Completed the mass production of the GLP ONX-1006 in kilogram scale
- Jul. 1, 2020 Signed a technology transfer agreement for Programmed Nanoparticle – Loaded Drug
- Mar. 19, 2020 Founding of company